BRIEF—Phoenix MD ready to test lead cancer candidate

Cancer specialist Phoenix Molecular Designs has completed clinical trial supply manufacture for its lead program PMD-026, the first RSK inhibitor built for the treatment of triple-negative breast cancer (TNBC).

The supply is being provided by WuXi STA, which has expanded its USA operations to include capsule production under GMP regulatory compliance.

Chief executive Sandra Dunn said: "The rapid achievement of this milestone brings us one step closer to initiating our study for women suffering from breast cancer.”

“RSK2 is a promising new drug target for the treatment of TNBC, and PMD-026 is the first drug to ever reach clinical use against this novel target."